425: Alumis and ACELYRIN Announce All-Stock Merger to Create Late-Stage Clinical Biopharma Company

Alumis and ACELYRIN are merging in an all-stock transaction to form a late-stage clinical biopharmaceutical company focused on immune-mediated diseases, with a combined cash position of approximately $737 million.

Summary

• Alumis and ACELYRIN have announced an all-stock merger to create a company focused on developing therapies for immune-mediated diseases.
• ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock owned.
• Alumis stockholders are expected to own approximately 55% of the combined company, while ACELYRIN stockholders will own approximately 45%.
• The combined company will operate under the name Alumis and will be led by the current Alumis executive team.
• The merger is expected to close in the second quarter of 2025, subject to stockholder approval and customary closing conditions.
• The pro forma cash position of the combined company is estimated to be around $737 million as of December 31, 2024, providing a cash runway into 2027.
• The combined company's pipeline includes ESK-001 (Phase 3 for psoriasis, Phase 2b for SLE), A-005 (Phase 2 for MS), and lonigutamab (Phase 2 for thyroid eye disease).
• Topline data from the Phase 3 ONWARD trials for ESK-001 in psoriasis is expected in the first half of 2026.
• Topline data from the Phase 2b LUMUS trial in systemic lupus erythematosus is expected in 2026.
• A Phase 2 clinical trial for A-005 in multiple sclerosis is expected to initiate in 2025, with topline data expected in 2026.
• The company plans to re-evaluate the development program for lonigutamab to confirm its differentiation in a capital efficient manner.

Sentiment

Score: 7

Explanation: The document presents a positive outlook due to the merger creating a well-capitalized company with a diversified pipeline. However, risks associated with the merger and drug development temper the overall sentiment.

Positives

• The merger creates a well-capitalized company with approximately $737 million in pro forma cash.
• The combined company has a diversified pipeline with multiple near-term milestones expected.
• The cash runway extends into 2027, beyond multiple expected clinical data readouts.
• The leadership team has a proven track record of operating discipline and capital efficiency.
• The combined company has three potential best-in-class molecules: two advanced clinical TYK2 inhibitors and an IGF-1R inhibitor.
• ESK-001 has near-term pivotal data expected in large indications.
• A-005 is a potentially first-in-class fully CNS-penetrant TYK2 inhibitor.
• Lonigutamab has a potentially differentiated profile with favorable efficacy and safety data in TED.

Negatives

• The merger is subject to stockholder approval and customary closing conditions, which could delay or prevent the transaction.
• The anticipated benefits and synergies of the proposed transaction may not be fully realized or may take longer to realize than expected.
• Integrating ACELYRIN's operations and personnel may present challenges.
• The company plans to re-evaluate the development program for lonigutamab which may lead to delays or changes in the development plan.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals of the proposed transaction may not be received.
• The announcement, pendency, or completion of the proposed transaction may negatively impact Alumis's or ACELYRIN's ability to attract and retain key personnel.
• The proposed transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the proposed transaction could arise.
• Alumis or ACELYRIN may be adversely affected by economic, business, and/or competitive factors.
• Restrictions during the pendency of the proposed transaction may impact Alumis's or ACELYRIN's ability to pursue certain business opportunities.
• The value of Alumis securities to be issued in the proposed transaction may fluctuate.
• Integration of the proposed transaction post-closing may not occur as anticipated.
• The combined company may not be able to achieve the growth prospects expected from the transaction.
• Legislative, regulatory, economic, competitive, and technological changes could impact the company.
• There are risks related to developing, commercializing, manufacturing, launching, marketing, and selling potential existing and new products and product candidates.
• Uncertainties exist in contractual relationships, including collaborations, partnerships, licensing, or other arrangements.
• The ability of each of Alumis and ACELYRIN to establish and maintain intellectual property protection for products or avoid or defend claims of infringement is not guaranteed.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials could occur.

Future Outlook

The combined company expects its pro forma financial plans to extend its cash runway into 2027, beyond multiple expected clinical readouts.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation to create companies with stronger financial positions and more diversified pipelines. This allows for greater efficiency in drug development and commercialization, particularly in the competitive field of immune-mediated diseases.

Comparison to Industry Standards

• The combined company's focus on TYK2 inhibitors places it in competition with companies like Bristol Myers Squibb, which has Sotyktu (deucravacitinib), an approved TYK2 inhibitor for psoriasis.
• The $737 million pro forma cash position is substantial, allowing the company to advance its pipeline through key clinical milestones, similar to how companies like Viking Therapeutics are funded to advance their metabolic disease programs.
• The focus on immune-mediated diseases aligns with the strategies of major pharmaceutical companies like AbbVie and Johnson & Johnson, which have established franchises in this therapeutic area.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the merger through the exchange of shares and potential future value creation.
• Employees of both companies may experience changes in roles and responsibilities as a result of the integration.
• Patients with immune-mediated diseases could benefit from the development of new therapies.
• The combined company's suppliers and partners may see changes in their relationships.

Next Steps

• Alumis and ACELYRIN stockholders need to approve the merger.
• The registration statement and joint proxy statement/prospectus will be filed with the SEC.
• The company will finalize plans for lonigutamab development.
• The company will initiate a Phase 2 clinical trial for A-005 in MS in 2H 2025.
• The company will pursue IND filing for a 3rd clinical candidate in 2H 2025.

Key Dates